Medeon Biodesign (6499.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · Taiwan · ISIN TW0006499007

Price

72.80 TWD

Market cap

7.06 bn TWD

P/E (2025)

–

P/S (2025)

16.83

Dividend yield

0.00 %

Net margin

-159.28 %

Return on equity (ROE)

-43.47 %

Return on assets (ROA)

-37.54 %

Medeon Biodesign financials

Fiscal year	2024	2025
Revenue	292.81 m TWD	419.43 m TWD
Gross profit	83.41 m TWD	58.83 m TWD
Operating income	-872.20 m TWD	-722.45 m TWD
EBIT	-853.09 m TWD	-716.01 m TWD
Net income	-805.51 m TWD	-668.06 m TWD
Diluted EPS – continuing operations	-8.74 TWD	-6.89 TWD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.